{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:39:13Z","timestamp":1791812353369,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.atherosclerosis.2016.03.003","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T14:54:03Z","timestamp":1457189643000},"page":"200-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"special_numbering":"C","title":["The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis"],"prefix":"10.1016","volume":"249","author":[{"given":"Nathalie","family":"Hennuyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Duplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Vanhoutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Woitrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Touche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Vallez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lestavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib1","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nri3520","article-title":"Macrophages in atherosclerosis: a dynamic balance","volume":"13","author":"Moore","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib3","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.bbalip.2007.04.021","article-title":"PPARalpha in atherosclerosis and inflammation","volume":"1771","author":"Zandbergen","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/ncpcardio1278","article-title":"Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease","volume":"5","author":"Staels","year":"2008","journal-title":"Nat. Clin. Pract. Cardiovasc Med."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1475-2840-11-125","article-title":"Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction","volume":"11","author":"Tenenbaum","year":"2012","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2174\/156802612799436641","article-title":"General molecular biology and architecture of nuclear receptors","volume":"12","author":"Pawlak","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib8","doi-asserted-by":"crossref","first-page":"27307","DOI":"10.1074\/jbc.272.43.27307","article-title":"Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice","volume":"272","author":"Peters","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib9","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1002\/j.1460-2075.1996.tb00918.x","article-title":"PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a ppre in the lipoprotein lipase gene","volume":"15","author":"Schoonjans","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib10","doi-asserted-by":"crossref","first-page":"17982","DOI":"10.1074\/jbc.M212191200","article-title":"Apolipoprotein a5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators","volume":"278","author":"Vu-Dac","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI117717","article-title":"Fibrates downregulate apolipoprotein c-iii expression independent of induction of peroxisomal acyl coenzyme a oxidase. a potential mechanism for the hypolipidemic action of fibrates","volume":"95","author":"Staels","year":"1995","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib12","doi-asserted-by":"crossref","first-page":"13470","DOI":"10.1074\/jbc.270.22.13470","article-title":"Mode of action of peroxisome proliferators as hypolipidemic drugs. suppression of apolipoprotein c-iii","volume":"270","author":"Hertz","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib13","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/S0022-2275(20)41090-9","article-title":"Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein c-iii expression: a potential physiologic basis for their mode of action","volume":"36","author":"Haubenwallner","year":"1995","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib14","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1093\/eurheartj\/ehs227","article-title":"Activation of intestinal peroxisome proliferator-activated receptor-\u03b1 increases high-density lipoprotein production","volume":"34","author":"Colin","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib15","doi-asserted-by":"crossref","first-page":"31012","DOI":"10.1016\/S0021-9258(18)47383-8","article-title":"Negative regulation of the human apolipoprotein a-i promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element","volume":"269","author":"Vu-Dac","year":"1994","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib16","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI118687","article-title":"Opposite regulation of human versus mouse apolipoprotein a-i by fibrates in human apolipoprotein a-i transgenic mice","volume":"97","author":"Berthou","year":"1996","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/01.RES.0000053386.46813.E9","article-title":"Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages","volume":"92","author":"Chinetti","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/83348","article-title":"PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the abca1 pathway","volume":"7","author":"Chinetti","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib19","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1161\/01.CIR.101.20.2411","article-title":"Cla-1\/sr-bi is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors","volume":"101","author":"Chinetti","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/01.CIR.0000086981.09834.E0","article-title":"Overexpression of apolipoprotein a-i promotes reverse transport of cholesterol from macrophages to feces in\u00a0vivo","volume":"108","author":"Zhang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/01.RES.0000185320.82962.F7","article-title":"Increased atherosclerosis in mice lacking apolipoprotein a-i attributable to both impaired reverse cholesterol transport and increased inflammation","volume":"97","author":"Moore","year":"2005","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib22","doi-asserted-by":"crossref","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors nf-kappab and ap-1","volume":"274","author":"Delerive","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib23","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/31701","article-title":"Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators","volume":"393","author":"Staels","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib25","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1161\/01.CIR.99.24.3125","article-title":"PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells","volume":"99","author":"Marx","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib26","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/ATVBAHA.110.220525","article-title":"Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein e2 knock-in mice","volume":"31","author":"Lalloyer","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib27","doi-asserted-by":"crossref","first-page":"48051","DOI":"10.1074\/jbc.M206966200","article-title":"Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice","volume":"277","author":"Duez","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11010-005-9053-y","article-title":"Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in ldl receptor-deficient mice","volume":"285","author":"Srivastava","year":"2006","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib29","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.106.684704","article-title":"Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"116","author":"Babaev","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib30","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib31","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(10)60758-1","article-title":"Fibrates in cvd: a step towards personalised medicine","volume":"375","author":"Staels","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib32","first-page":"1","article-title":"Early investigational drugs targeting PPAR-\u03b1 for the treatment of metabolic disease","author":"Liu","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ncpendmet0397","article-title":"Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors","volume":"3","author":"Gervois","year":"2007","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor \u03b1 modulators (spparm\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib35","first-page":"A12867","article-title":"The mechanisms of k-877, a highly potent and selectiveppara modulator, on regulation of synthesis, secretion and metabolisms of triglycerides and cholesterol","volume":"128","author":"Takizawa","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib36","first-page":"A10718","article-title":"Efficacy and safety of k-877, a potent and selective PPARa agonist, in Japanese patients with dyslipidemia","volume":"128","author":"Ishibashi","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib37","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1161\/ATVBAHA.113.301468","article-title":"Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities","volume":"33","author":"Camont","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5551\/jat.E571","article-title":"Antiatherogenic functionality of high density lipoprotein: how much versus how good","volume":"15","author":"Sviridov","year":"2008","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib39","first-page":"A15652","article-title":"Comparison of the effect of novel peroxisome proliferator-activated receptor alpha agonist k-877 and fenofibrate on high density lipoprotein subclass distribution determined by high-performance liquid chromatography in patients with dyslipidemia","volume":"128","author":"Yamashita","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2011.05.013","article-title":"Biological activities of hdl subpopulations and their relevance to cardiovascular disease","volume":"17","author":"Camont","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib41","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"Hdl cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbalip.2010.11.006","article-title":"Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in\u00a0vivo","volume":"1811","author":"Rotllan","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2016.03.003_bib43","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1073\/pnas.0538015100","article-title":"Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase","volume":"100","author":"Ziouzenkova","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T15:04:14Z","timestamp":1654614254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016300788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":43,"alternative-id":["S0021915016300788"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.03.003","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}